Chapter 44 Field specific visual evoked potentials for assessment of peripheral field defect in a paediatric population

Supplements to Clinical Neurophysiology

Volumn 53, Issue C, 2000, Pages 323-330

  Harding, G F A ^a   Robertson, K A ^a   Holliday, I ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN;

ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; EPILEPSY; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; VISUAL DISORDER; VISUAL FIELD;

ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; EPILEPSY; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MALE; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 0006189915     PISSN: 1567424X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-424X(09)70175-8     Document Type: Article

References (26)

1. Appleton R.E. Guideline may help in prescribing vigabatrin. Br. Med. J. 317 (1998) 1322
2. Arezzo J.C., Schroeder C.E., Litwak M.S., and Steward D.L. Effects of vigabatrin on evoked potentials in dogs. Br. J. Clin. Pharmacol. 27 (1989) 53S-60S
3. Butler W.H., Ford G.P., and Newbeme J.W. A study of the effects of vigabatrin on the central nervous system and retina of Sprague-Dawley and Lister-hooded rats. Toxicol. Pathol. 15 (1987) 143-148
4. Drasdo N. The neural representation of visual space. Nature 266 5602 (1977) 544-556
5. Drasdo N., and Thompson D. An optical stimulator for studying the topography of electrical and magnetic visual evoked responses. Documenta Ophthal 81 (1992) 219-225
6. Duckett T., Brigell M., and Ruckh S. Electroretinographic changes are not associated with loss of visual function in paediatric epileptic patients following treatment with vigabatrin. Invest. Ophthalmol. Vis. Sci. 39 4 (1998) 973
7. Eke T., Talbot J.F., and Lawden M.C. Severe persistent visual field constriction associated with vigabatrin. Br. Med. J. 314 (1997) 180-181
8. Gibson J.P., Yarrington J.T., Loudy D.E., Gerbig C.G., et al. Chronic toxicity studies with vigabatrin: a GABA-transaminase inhibitor. Toxicol. Pathol. 18 (1990) 225-238
9. Graham D. Neuropathology of vigabatrin. Br. J. Clin. Pharmacol. 27 (1989) 43S-45S
10. Gram L., Klosterskov P., and Dam M. Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann. Neurol. 17 (1985) 262-266
11. Haegele K.D., and Schecter P.J. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin. Pharmacol. Ther. 40 (1986) 581-586
12. Harding G.F.A., Jones L.A., Tipper V.J., Betts T.A., and Mumford J.P. Electroretinogram, pattern electroretinogram and visual evoked potential assessment in patients receiving vigabatrin. Epilepsia 36 (1995) 30
13. Harding G.F.A. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist. Br. Med. J. 314 7095 (1997) 1694
14. Harding G.F.A., Wild J.M., Robertson K.A., Edson A., Barber C., Lawden M., and Betts T. Electrooculography, ERGs, multi-focal ERGs and VEPs in epileptic patients showing visual field disorders. Electroenceph. clin. Neurophysiol. 103 (1997) 96
15. Harding G.F.A., Wild J.M., Robertson K.A., Lawden M., Betts T.A., Barber C.M., and Barnes P.M.F. EOGs, ERGs, VEPs and Multifocal ERGs in epileptic patients showing visual field constriction. Epilepsia (2000) (in press)
16. Kälviäinen R., Aikiä M., Mervaala E., et al. Vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy. Arch. Neurol. 52 (1995) 989-996
17. Krauss G.L., Johnson M.A., and Miller N.R. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram and ophthalmic findings. Neurology 50 3 (1998) 614-618
18. Kurita-Tashima S., Tobamitsu S., Nakayama-Hiromatsu M., and Kato M. Effect of check size on pattern reversal visual evoked response. Electroenceph. clin. Neurophysiol. 80 (1991) 161-166
19. Lawden M.C., Eke T., Degg C., Harding G.F.A., and Wild J.M. Visual field defects associated with vigabatrin therapy. J. Neurol. Neurosurg. Psychiatry 67 (1999) 716-722
20. Mauguière F., Chauvel P., Dewailly J., and Dousse N. No effect of long-term vigabatrin treatment on CNS conduction in epileptic patients: results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 36 3 (1995) 29
21. Mumford J.P. Tolerability and safety profile of vigabatrin. Rev. Contemp. Pharmacother. - Vigabatrin 6 9 (1995) 477-483
22. Patsalos P.N., and Duncan J.S. The pharmacology and pharmaco-kinetics of vigabatrin. Rev. Contemp. Pharmacother. - Vigabatrin 6 9 (1995) 447-456
23. Vies J.S.H., van den Heyden A.M.G.H., Ghijs A., et al. Vigabatrin in the treatment of infantile spasms. Neuropediatrics 24 (1993) 230-231
24. Sokol S., and Dobson M.V. Pattern reversal visually evoked potentials in infants. Invest. Ophthalmol. Vis. Sci. 15 (1976) 58-62
25. Blumhardt L., Barrett G., and Halliday A.M. The asymmetrical visual evoked potential to pattern reversal in one half field and its significance for the analysis of visual field defect. Br. J. Ophthalmol. 61 (1977) 456-461
26. Wild J.M., Martinez C., Reinshagen G., and Harding G.F.A. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia (2000) (in press)